Literature DB >> 11224603

Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior.

R E Jimenez1, T Wallis, D W Visscher.   

Abstract

Most breast carcinomas exhibit ductal differentiation. However, recognition of less common histologic patterns provides clinically useful data. This report describes a distinctive subtype of breast carcinoma that we have termed "centrally necrotizing carcinoma" (CNC; in this study, N = 34), which is characterized by an unusual and aggressive natural history. Centrally necrotizing carcinomas are composed of well-circumscribed, unicentric nodules with extensive central necrosis that are surrounded by a narrow rim of viable high-grade tumor cells. These tumor cells show minimal ductal differentiation (i.e., tubule formation), but are usually associated with focal ductal carcinoma in situ. The mean age of the patients in this study was 57.5 +/- 11.6 years, and the mean tumor size was 2.5 +/- 1.2 cm. Twenty-eight percent of the patients had positive axillary lymph nodes (mean number of lymph nodes involved, 2.1 +/- 1.2). Ninety-four percent of cases were negative for estrogen and progesterone receptors. In 21 patients (62%), local and/or distant recurrences developed (median time to recurrence, 16.2 months), and, to date, 20 have died from breast cancer (median time to death, 22.5 months). Progression of disease (defined as the development of either a recurrence or death resulting from disease) occurred in 24 patients (71%). Comparison with a set of 26 poorly differentiated ductal carcinomas with (nonextensive, patchy) necrosis matched for age, tumor size, and lymph node status showed a significantly worse progression-free survival rate for the CNC group (p < 0.004). We conclude that CNC is an uncommon but readily identifiable subtype of breast carcinoma and is characterized by early systemic metastasis and an accelerated clinical course.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11224603     DOI: 10.1097/00000478-200103000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

1.  Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy.

Authors:  Takayoshi Uematsu; Masako Kasami; Sachiko Yuen
Journal:  Eur Radiol       Date:  2010-05-09       Impact factor: 5.315

2.  Triple-negative breast cancers: an updated review on treatment options.

Authors:  K B Reddy
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

3.  Pathological features of Breast Cancer seen in Northwestern Tanzania: a nine years retrospective study.

Authors:  Peter F Rambau; Philipo L Chalya; Mange M Manyama; Kahima J Jackson
Journal:  BMC Res Notes       Date:  2011-06-22

4.  The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype.

Authors:  Xiao Wang; Lan Chao; Guohui Ma; Liansheng Chen; Yixiu Zang; Jingzhong Sun
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-18       Impact factor: 4.553

5.  Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.

Authors:  Eugenio Maiorano; Meredith M Regan; Giuseppe Viale; Mauro G Mastropasqua; Marco Colleoni; Monica Castiglione-Gertsch; Karen N Price; Richard D Gelber; Aron Goldhirsch; Alan S Coates
Journal:  Breast Cancer Res Treat       Date:  2009-03-12       Impact factor: 4.872

Review 6.  Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).

Authors:  Abeer H Abdelhafez; Benjamin C Musall; Wei T Yang; Gaiane M Rauch; Beatriz E Adrada; KennethR Hess; Jong Bum Son; Ken-Pin Hwang; Rosalind P Candelaria; Lumarie Santiago; Gary J Whitman; Huong T Le-Petross; Tanya W Moseley; Elsa Arribas; Deanna L Lane; Marion E Scoggins; Jessica W T Leung; Hagar S Mahmoud; Jason B White; Elizabeth E Ravenberg; Jennifer K Litton; Vicente Valero; Peng Wei; Alastair M Thompson; Stacy L Moulder; Mark D Pagel; Jingfei Ma
Journal:  Breast Cancer Res Treat       Date:  2020-09-13       Impact factor: 4.872

7.  Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer.

Authors:  Michael Z Gilcrease; Xiao Zhou; Xiaolin Lu; Wendy A Woodward; Brian E Hall; Phillip J Morrissey
Journal:  J Exp Clin Cancer Res       Date:  2009-05-26

8.  Clinicopathological study of centrally necrotizing carcinoma of the breast.

Authors:  Yanling Zhang; Yurong Ou; Donghong Yu; Xiang Yong; Xiaoli Wang; Bo Zhu; Qiong Zhang; Lei Zhou; Zhaogen Cai; Zenong Cheng
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

9.  Centrally necrotizing breast carcinoma: a rare histological subtype, which was cause of misdiagnosis in an evident clinical local recurrence.

Authors:  Fernando Hernanz; Pilar Alonso-Bartolomé; Irene González-Rodilla
Journal:  World J Surg Oncol       Date:  2012-08-01       Impact factor: 2.754

10.  Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI.

Authors:  J Veltman; R Mann; T Kok; I M Obdeijn; N Hoogerbrugge; J G Blickman; C Boetes
Journal:  Eur Radiol       Date:  2008-02-13       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.